As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Systemic Lupus Erythematosus Package


> Download your free sample > Contact us to find out more



This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 108 high prescribing rheumatologists and detailed discussions with KOLs.  Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics/biosimilars) will affect the market in the future.

The Datamonitor Healthcare difference

What this package includes

Total number of physicians interviewed


Rheumatologists 108

Coverage summary

Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Patient-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Patient-based drug forecast period 2012–22
Patient subpopulations forecasted
  • Severity (mild, moderate, severe)
Drugs profiled
  • Benlysta
  • CellCept (off-label)
  • Rituxan (off-label)
  • Lupuzor
  • atacicept
  • blisibimod
  • epratuzumab
  • tabalumab



Key Findings

Following the long-awaited US Food and Drug Administration (FDA) approval of Benlysta, rapid uptake of the drug in moderate to severe patients was expected. However, company-reported sales show that uptake has been slow. Still, Benlysta’s sales are forecast to continue to increase and its position will be somewhat insulated by its first-to-market status, particularly as its subcutaneous formulation is forecast to reach the market ahead of the competition. As a result, it is forecast to remain the highest selling drug for lupus during the forecast period (2013–22), with sales split between its two formulations. The unexpectedly slow increase in the uptake and sales of Benlysta despite the enthusiasm surrounding its approval demonstrates the difficult road facing companies that attempt to penetrate the SLE market.

> Download your free sample > Contact us to find out more

Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726